New High Blood Pressure Guidelines

The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions.

 

nuevas-guias-de-hipertension

As expected, after the findings of the SPRINT trial and other recently published studies, the treatment goal was lowered and is now below 130/80 mm Hg.


Read also: FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI”.


Blood pressure (BP) levels considered “prehypertension,” according to the Seventh Joint National Committee (JNC 7), are now an “elevated BP” category for patients with systolic 120 to 129 mm Hg and diastolic less than 80 mm Hg, and stage 1 hypertension for patients with systolic 130 to 139 mm Hg and diastolic 80 to 89 mm Hg. Patients with a systolic BP above 140 mm Hg and a diastolic BP above 90 mm Hg are now encompassed in stage 2 hypertension.

 

The consequence of this reclassification is that almost half of the population (45.6%) is now deemed to have hypertension vs. 31.9% according to JNC 7 criteria.


Read also: PRESERVE: IV Bicarbonate and Oral N-Acetylcysteine Do Not Prevent Contrast-Associated Acute Kidney Injury”.


This guideline has been published online before print in Hypertension and the Journal of the American College of Cardiology, and it is the culmination of a process that started in 2013 and comprised the review of over 1000 studies. The resulting document covers the prevention, detection, evaluation, and management of high blood pressure in adults.

 

There is an emphasis on the importance of lifestyle modification, beyond the levels of blood pressure and cardiovascular risk of patients.

 

Original title: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Reference: Whelton PK et al. Hypertension. 2017; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...